GLP-1 receptor agonist · Evidence-led, sources cited
Ozempic (Semaglutide)
Licensed in the UK for type 2 diabetes — NOT for weight loss. The same molecule is licensed for weight management as Wegovy.
How it works
Ozempic is semaglutide licensed to improve blood-sugar control in type 2 diabetes. It is frequently discussed for weight because it shares the molecule used in Wegovy.
Published dosing
Published dosing relates to its diabetes licence. For weight management, the licensed product is Wegovy — your prescriber will advise what's appropriate and licensed for you.
Common side effects
As a GLP-1, commonly reported effects per the SmPC are gastrointestinal: nausea, diarrhoea, constipation.
What the evidence shows
Diabetes outcome trials support its glucose-lowering licence. For weight specifically, see the Wegovy evidence.